Article
Pharmacology & Pharmacy
Bin Pan, Lin Zheng, Jiawei Fang, Ye Lin, Hehuan Lai, Jiawei Gao, Wenzheng Pan, Yejin Zhang, Kainan Ni, Chao Lou, Dengwei He
Summary: Azilsartan inhibits osteoclastogenesis by reducing ROS production and may serve as a novel treatment strategy for osteoporosis caused by osteoclast overactivation.
FRONTIERS IN PHARMACOLOGY
(2021)
Review
Endocrinology & Metabolism
Jie Han, Kuan Yang, Jinyang An, Na Jiang, Songbo Fu, Xulei Tang
Summary: Bone metabolism is closely related to oxidative stress, and NRF2, as a core regulatory factor, plays a complex and controversial role in bone homeostasis. Moderate activation of NRF2 promotes increased bone mass, while hyperactivation may cause damage to bone formation.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Pharmacology & Pharmacy
Wenjie Liu, Gang Xie, Guixin Yuan, Dantao Xie, Zhen Lian, Zihong Lin, Jiajie Ye, Wenyun Zhou, Weijun Zhou, Henghui Li, Xinjia Wang, Haotian Feng, Ying Liu, Guanfeng Yao
Summary: 6'-O-Galloylpaeoniflorin (GPF), a natural antioxidant isolated from peony roots, shows potential in attenuating osteoclastogenesis and relieving ovariectomy-induced osteoporosis by inhibiting ROS activity, MAPKs/c-Fos/NFATc1 signaling pathway, and osteoclast-specific gene expression. In vivo studies indicate that GPF can prevent bone loss in ovariectomized mice, suggesting its potential application in treating bone diseases associated with osteoclasts.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Cynthia Sithole, Carla Pieterse, Kayla Howard, Abe Kasonga
Summary: Osteoclasts are cells responsible for bone resorption, with GPR120 signaling possibly inhibiting their formation and resorption by suppressing ROS production. The GPR120 agonist TUG-891 can inhibit osteoclast formation and resorption by suppressing ROS production.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Biochemistry & Molecular Biology
Yinglong Xu, Dezhi Song, Xixi Lin, Hui Peng, Yuangang Su, Jiamin Liang, Na Hai, Jinmin Zhao, Qian Liu
Summary: Corylifol A can prevent estrogen-deficiency-induced bone loss by inhibiting osteoclastogenesis and intracellular ROS levels. This study also found that Corylifol A has no effect on cortical bone in ovariectomized mice.
FREE RADICAL BIOLOGY AND MEDICINE
(2023)
Article
Endocrinology & Metabolism
Xiaoli Zhao, Shuai Lin, Huiying Li, Shuyi Si, Zhen Wang
Summary: The study shows that MPO plays a protective role in bone turnover by limiting osteoclastogenesis and bone resorption through modulating intracellular H2O2 level.
JOURNAL OF BONE AND MINERAL RESEARCH
(2021)
Review
Immunology
Dao-Fang Ding, Yan Xue, Xi-Chen Wu, Zhi-Heng Zhu, Jia-Ying Ding, Yong-Jia Song, Xiao-Ling Xu, Jian-Guang Xu
Summary: This article summarizes the potential of third-generation ROS-sensitive nanomaterials in treating osteoarthritis. Polymer-based nanoparticles have unique characteristics, such as scavenging excessive ROS in vivo, and are of great significance for OA therapy.
JOURNAL OF INFLAMMATION RESEARCH
(2022)
Article
Cell Biology
Qingxuan Wang, Jing Xie, Chenchen Zhou, Wenli Lai
Summary: The stiffness of the substrate plays a crucial role in osteoclast differentiation and function, with higher stiffness accelerating osteoclast formation and activity. Higher stiffness substrates can also activate cytoskeletal adhesion molecules and biochemical signaling cascades.
CELL PROLIFERATION
(2022)
Article
Chemistry, Medicinal
Shuan-Jing Wang, Jiahui Zhang, Jing-Zan Zhang, Ruo-Nan Ning, Chen-Chen Li, Xing Xu, Min Jiang, Wen-Wei Qiu
Summary: A series of heterocyclic ring-fused derivatives of 20(S)-protopanaxadiol (PPD) were synthesized and evaluated for their inhibitory effects on RANKL-induced osteoclastogenesis. Compound 33 (SH491) showed the highest potency with 100% inhibition at 0.1 μM and 44.4% inhibition at 0.01 μM, surpassing the lead compound PPD. Cytotoxicity tests indicated that the inhibitory effect was not due to cytotoxicity, and SH491 also affected osteoblastogenesis.
JOURNAL OF MEDICINAL CHEMISTRY
(2023)
Article
Oncology
Lu Zhang, Guangjun Jiao, Yunhao You, Xiang Li, Jincheng Liu, Zhenqian Sun, Qinghui Li, Zihan Dai, Jinlong Ma, Hongming Zhou, Gang Li, Chunyang Meng, Yunzhen Chen
Summary: In this study, it was discovered that coactivator-associated arginine methyltransferase 1 (CARM1) affects the metabolism of osteoblasts and osteoclasts, thereby promoting osteogenesis and inhibiting osteoclast differentiation. By altering carbohydrate metabolism, CARM1 can reduce bone loss in osteoporosis model mice. These findings may provide a new feasible treatment strategy for osteoporosis.
CLINICAL AND TRANSLATIONAL MEDICINE
(2023)
Article
Engineering, Environmental
Yonggang Ma, Di Ran, Ying Cao, Hongyan Zhao, Ruilong Song, Hui Zou, Jianhong Gu, Yan Yuan, Jianchun Bian, Jiaqiao Zhu, Zongping Liu
Summary: Long-term exposure to cadmium inhibits osteogenesis of bone marrow stem cells and differentiation of bone marrow macrophages, leading to osteoporosis. P2X7 plays a crucial role in this process, with its deletion or overexpression affecting bone cell differentiation. Short-term exposure to cadmium inhibits bone formation, increases osteoclast numbers, but does not result in osteoporosis.
JOURNAL OF HAZARDOUS MATERIALS
(2021)
Article
Orthopedics
Yu-Cong Lin, Guan Zheng, Hua-Tao Liu, Peng Wang, Wei-Quan Yuan, Yun-Hui Zhang, Xiao-Shuai Peng, Guo-Jian Li, Yan-Feng Wu, Hui-Yong Shen
Summary: This study reveals that USP7 promotes the differentiation of CD14+ PBMCs into osteoclasts through the deubiquitination of HMGB1. Inhibition of USP7 effectively attenuates bone loss in osteoporosis. These findings provide novel insights into the role of USP7 in osteoporosis and suggest a new therapeutic target for its treatment.
JOURNAL OF ORTHOPAEDIC TRANSLATION
(2023)
Review
Endocrinology & Metabolism
Pan Sun, Tingrui Huang, Chen Huang, Yongjun Wang, Dezhi Tang
Summary: Osteoporosis is a degenerative bone disease characterized by reduced bone mass and damage to bone microarchitecture, leading to increased bone fragility and susceptibility to fractures. The risk of osteoporosis increases with age, and it is becoming more prevalent due to the aging global population. Histone modifications play an important role in the occurrence and development of osteoporosis, and targeting these modifications to promote bone formation may be an effective treatment strategy.
FRONTIERS IN ENDOCRINOLOGY
(2022)
Article
Plant Sciences
Yun Yang, Qiu Wei, Ran An, Hua-mei Zhang, Jia-yuan Shen, Xiao-yan Qin, Xiao-ling Han, Jie Li, Xiao-wei Li, Xiu-mei Gao, Jun He, Hao-ping Mao
Summary: This study aimed to investigate the potential effect of Semen Cuscutae on ovariectomy (OVX)-induced osteoporosis in mice and clarify the exact mechanisms by which Semen Cuscutae exert the anti-osteoporosis effect.
JOURNAL OF ETHNOPHARMACOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Mina Ding, Zhihao Chen, Eunjin Cho, Sang-Wook Park, Tae-Hoon Lee
Summary: This study identifies GSK2879552, a LSD1 inhibitor, as a potential treatment for osteoporosis by inhibiting osteoclast differentiation. LSD1 inhibitors effectively inhibit RANKL-induced osteoclastogenesis and prevent the expression of osteoclast-specific genes. Inhibition of LSD1 activities may be a potential target for preventing bone diseases characterized by excessive osteoclast activities.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
